Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

To compare the time to hyperglycaemia recovery after ultra rapid lispro (URLi; Lyumjev®) versus Humalog in a randomized, double-blind crossover study.

Who Took Part

PubMed indexes the participants as adults.

Thirty-two adults with type 1 diabetes on continuous subcutaneous insulin infusion participated in two periods: each period included hyperglycaemia induced by a missed mealtime bolus (day 1) and by suspension of basal insulin delivery (day 2).

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Insulin Lispro, so expectations could not easily colour the readings.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Insulin Lispro, Diabetes Mellitus, Type 1, Hyperglycemia, Hypoglycemic Agents, Insulin and Blood Glucose.

The authors tagged it with the keywords hyperglycaemia, rapid-acting insulin and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Lispro compound page, all human trials.